<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03899324</url>
  </required_header>
  <id_info>
    <org_study_id>CUREPARK/OP105018.BAT</org_study_id>
    <nct_id>NCT03899324</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease</brief_title>
  <acronym>CUREPARK</acronym>
  <official_title>A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B&amp;A Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B&amp;A Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multicentre, proof of concept, randomized, double-blind, parallel-group,&#xD;
      placebo-control study in 40 Parkinson's Disease (PD) patients. Patients will be randomized in&#xD;
      2 groups receiving Bumetanide or placebo for 4 months:&#xD;
&#xD;
        -  Group 1 (20 PD patients): bumetanide&#xD;
&#xD;
        -  Group 2 (20 PD patients): placebo intake identically to group 1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of this study is the change from baseline (V2) to endpoint (V5) in the MDS-UPDRS III motor score, evaluated 1 hour after the intake of the study treatment (Bumetanide or placebo) in patients in the OFF state.</measure>
    <time_frame>Between Day 1 and Day 120</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from V2 to V5 of the MDS-UPDRS part III and part I measured in a patient in the ON state.</measure>
    <time_frame>Between Day 1 and Day 120</time_frame>
    <description>Movement Disorder Society Unified Parkinson's Disease Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of scores of the MDS-UPDRS part II, III and IV during the trial, at D1 (V2), D30 (V3), D60 (V4) and D120 (V5).</measure>
    <time_frame>Day 1, Day 30, Day 60, Day 120</time_frame>
    <description>Movement Disorder Society Unified Parkinson's Disease Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stand-Walk-Sit test at D1 (V2), D30 (V3), D60 (V4) and D120 (V5).</measure>
    <time_frame>Day 1, Day 30, Day 60, Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events collected at each visit and phone calls.</measure>
    <time_frame>Throughout the completion of the study, from Day 1 to Day 135</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Unified dyskinesia rating scale at D1 (V2), D30 (V3), D60 (V4) and D120 (V5).</measure>
    <time_frame>Day 1, Day 30, Day 60, Day 120</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Awaken time spent in the OFF state, in the ON state with and without dyskinesia.</measure>
    <time_frame>Between Day 0 (Screening) and Day 1 (V2), then between Day 60 (V4) and Day 120 (V5)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient's Clinical Global Impression (CGI) score at D1 (V2), D30 (V3), D60 (V4) and D120 (V5).</measure>
    <time_frame>Day 1, Day 30, Day 60, Day 120</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Group 1: Experimental Bumetanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bumetanide with a titration period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo intake identically to group 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bumetanide white, oblong, scored tablet</intervention_name>
    <description>Bumetanide with a titration period</description>
    <arm_group_label>Group 1: Experimental Bumetanide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo white, oblong, scored tablet</intervention_name>
    <description>placebo intake identically to group 1</description>
    <arm_group_label>Group 2: Placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Idiopathic Parkinson's disease fulfilling the UK Parkinson's Disease Brain Bank&#xD;
             (UKPDSBB) criteria (cf. Appendix VII)&#xD;
&#xD;
          2. 40 &lt; Age &lt; 80 years old&#xD;
&#xD;
          3. Hoehn &amp; Yahr 1.5-4 (OFF stage)&#xD;
&#xD;
          4. Walking and balance or freezing ≥ 1in the MDS-UPDRS II&#xD;
&#xD;
          5. Motor fluctuation defined by a score ≥ 1 on the item &quot;time spent in the OFF state&quot; of&#xD;
             the MDS-UPDRS IV&#xD;
&#xD;
          6. Dose of L-DOPA ≥ 150 mg/d (concomitant treatment)&#xD;
&#xD;
          7. PD medications regimen stable for at least 3 months&#xD;
&#xD;
          8. Patients expected to remain on stable doses of PD medications during all the study&#xD;
&#xD;
          9. Covered by Health Insurance System&#xD;
&#xD;
         10. Able to understand and to sign the informed consent prior to selection&#xD;
&#xD;
         11. Negative pregnancy test at screening&#xD;
&#xD;
         12. Blood Pressure (BP) and Heart Rate (HR) considered Non Clinicaly Significant (NCS) by&#xD;
             investigators&#xD;
&#xD;
         13. Electrocardiogram (ECG) recording on a 12-lead ECG considered NCS by investigators&#xD;
&#xD;
         14. Laboratory parameters within the normal range of the laboratory. Individual values out&#xD;
             of the normal range can be accepted if judged clinically non relevant by the&#xD;
             Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Atypical parkinsonism or drug-induced parkinsonism&#xD;
&#xD;
          2. Cognitive impairment (MMSE ≤ 24)&#xD;
&#xD;
          3. Active psychiatric disorder (mood disorders, hallucinations or delirium with strong&#xD;
             functional impact and not controlled by medication or which happened during the last 3&#xD;
             months before inclusion)&#xD;
&#xD;
          4. Treatment by Deep Brain Stimulation or continuous infusion of apomorphin/dopa gel&#xD;
&#xD;
          5. Renal or hepatic insufficiency&#xD;
&#xD;
          6. Electrolyte disturbances&#xD;
&#xD;
          7. A corrected QT (QTcF) interval &gt;450ms for male or &gt;470ms for female on the&#xD;
             electrocardiogram&#xD;
&#xD;
          8. Any medical condition that might interfere with the protocol except those defined in&#xD;
             Section 5.3&#xD;
&#xD;
          9. Contraindications to bumetanide : persistent anuria, hepatic encephalopathy included&#xD;
             coma&#xD;
&#xD;
         10. Women pregnant, nursing or of childbearing age without effective contraception.&#xD;
             Patients should not be enrolled if they plan to become pregnant during the time of&#xD;
             study participation&#xD;
&#xD;
         11. Patient unable to attend scheduled visits or to comply to the protocol&#xD;
&#xD;
         12. Patient under legal guardianship or judicial protection&#xD;
&#xD;
         13. Patient in the exclusion period of another protocol&#xD;
&#xD;
         14. No possibility of contact in case of emergency&#xD;
&#xD;
         15. Known allergic reactions induced by Burinex (Bumetanide)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Denis Ravel, PhD</last_name>
    <phone>04 38 37 27 40</phone>
    <email>denis.ravel@initial-rd.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fanny Kayser</last_name>
    <phone>04 38 37 27 40</phone>
    <email>OP1050@eurofins.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LE DILY Séverine</last_name>
      <phone>02 40 16 52 86</phone>
    </contact>
    <investigator>
      <last_name>Philippe DAMIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Damier P, Hammond C, Ben-Ari Y. Bumetanide to Treat Parkinson Disease: A Report of 4 Cases. Clin Neuropharmacol. 2016 Jan-Feb;39(1):57-9. doi: 10.1097/WNF.0000000000000114.</citation>
    <PMID>26757306</PMID>
  </reference>
  <reference>
    <citation>Lozovaya N, Eftekhari S, Cloarec R, Gouty-Colomer LA, Dufour A, Riffault B, Billon-Grand M, Pons-Bennaceur A, Oumar N, Burnashev N, Ben-Ari Y, Hammond C. GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease. Nat Commun. 2018 Apr 12;9(1):1422. doi: 10.1038/s41467-018-03802-y.</citation>
    <PMID>29651049</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bumetanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

